Bone Health and Osteoporosis: Causes, Diagnosis, and Evidence-Based Treatment

What Is Osteoporosis and Why Does Bone Density Decline?

Osteoporosis develops when the rate of bone resorption chronically outpaces bone formation, leaving a porous, mechanically weakened skeleton. The World Health Organization defines the condition by a bone mineral density (BMD) T-score at or below -2.5 at the femoral neck, total hip, or lumbar spine on dual-energy X-ray absorptiometry (DXA). Approximately 10 million Americans already carry the diagnosis, and another 44 million have low bone mass that puts them at elevated fracture risk [1].

Bone is not static. It is constantly remodeled by two cell types working in opposition: osteoclasts that resorb old bone and osteoblasts that deposit new mineral matrix. Peak bone mass is typically reached between ages 25 and 30 [2]. After that, a slow net loss begins in both sexes. The balance tips more steeply in women after menopause, in men with hypogonadism, and in anyone taking chronic glucocorticoids.

The mechanical consequence of low density is fracture. A fragility fracture, meaning one caused by a fall from standing height or less, at the spine, hip, wrist, or shoulder is considered diagnostic of osteoporosis regardless of T-score. The National Osteoporosis Foundation estimates more than 2 million such fractures occur in the United States each year, with direct costs exceeding $19 billion [3].

How Menopause Accelerates Bone Loss

Estrogen is the dominant regulator of bone remodeling in women. It suppresses osteoclast activity and extends osteoblast survival. When estrogen levels fall during the menopausal transition, osteoclast-driven resorption accelerates sharply.

Studies show that women can lose between 1% and 3% of bone mass per year in the first five years after menopause, and some lose up to 20% of total bone mass across that window [4]. The trabecular bone of the lumbar spine, which has high surface-area contact with bone-resorbing cells, is hit first and hardest. Cortical bone at the hip follows over the next decade.

The RANK-L pathway explains much of this biology. Estrogen normally suppresses RANK-L, a cytokine that activates osteoclast precursors. Without estrogen, RANK-L rises, osteoclast activity surges, and micro-architectural deterioration proceeds even when absolute calcium intake is adequate [5]. This is why calcium supplementation alone cannot arrest menopausal bone loss.

The clinical relevance is significant. A woman who enters menopause with average bone mass and loses bone at the upper end of this range may cross the osteoporosis threshold before age 60, well before most primary-care screening protocols would catch her.

Men, Testosterone, and Bone Mineral Density

Osteoporosis in men is underdiagnosed. Roughly 2 million American men have the condition, and another 12 million have osteopenia [6]. Testosterone drives bone mass in men through two pathways: direct androgen receptor signaling in osteoblasts, and peripheral aromatization of testosterone to estradiol, which then suppresses osteoclast activity the same way ovarian estrogen does in women.

The Testosterone Trials (TTrials), a coordinated set of placebo-controlled studies in 788 hypogonadal men aged 65 and older, provided the clearest human evidence to date. Men randomized to testosterone gel 1% for 12 months showed statistically significant increases in volumetric BMD at the spine (P<0.001) and trabecular bone score compared to placebo [7]. The effect size was comparable to bisphosphonate therapy in that population.

A 2017 JAMA Internal Medicine analysis of the TTrials bone sub-study found that testosterone treatment increased estimated bone strength by 10.9% at the femoral neck. This was not a small-study finding. It involved rigorous DEXA and quantitative CT measurements across multiple sites. Men with total testosterone below 300 ng/dL showed the largest gains, consistent with the hypothesis that the benefit is driven by repleting a deficient signal rather than by supraphysiologic dosing.

HealthRX Bone-Loss Risk Stratification for Telehealth Patients (Working Framework)

Clinicians evaluating bone health in telehealth patients can apply a three-tier framework before ordering DXA:

• Tier 1 (low risk): Age <50, no fracture history, no glucocorticoid use, normal sex-hormone labs. Monitor clinically; standard dietary counseling.
• Tier 2 (moderate risk): Age 50-64 female or 60-69 male, one or more FRAX risk factors (low body weight, smoking, parental hip fracture, alcohol over 3 units/day), or hormone deficiency without replacement. Order DXA and FRAX. Consider pharmacotherapy if 10-year hip fracture probability exceeds 3% or major osteoporotic fracture probability exceeds 20%.
• Tier 3 (high risk): Prior fragility fracture, T-score at or below -2.5, long-term glucocorticoid use (prednisone 5 mg/day for 3 or more months), or active hypogonadism with bone symptoms. Initiate pharmacotherapy promptly; co-manage with endocrinology or rheumatology as needed.

Diagnosing Osteoporosis: DXA, FRAX, and When to Screen

DXA remains the standard diagnostic tool. It reports BMD in grams per square centimeter and converts that to a T-score (comparison to a young-adult reference population) and Z-score (comparison to age-matched peers). The T-score thresholds are: normal at -1.0 or above, osteopenia between -1.0 and -2.5, and osteoporosis at -2.5 or below.

The U.S. Preventive Services Task Force recommends DXA screening for all women aged 65 and older and for younger postmenopausal women whose 10-year fracture probability, calculated by the FRAX tool, equals or exceeds that of a 65-year-old white woman with no additional risk factors [8]. No equivalent universal screening recommendation exists for men, though AACE and the Endocrine Society suggest screening men aged 70 or older, or men aged 50 to 69 with risk factors such as hypogonadism or glucocorticoid exposure.

FRAX integrates clinical risk factors with or without femoral neck BMD to estimate 10-year probability of hip fracture and major osteoporotic fracture. Treatment thresholds widely used in North America are a 10-year major fracture probability above 20% or a hip fracture probability above 3% [9]. Vertebral fracture assessment (VFA) via DXA can identify silent spine fractures that reclassify patients to high risk even when BMD alone does not meet the osteoporosis threshold.

Calcium, Vitamin D, and Lifestyle: The Non-Negotiable Foundation

No drug works optimally without adequate calcium and vitamin D. The National Academy of Medicine recommends 1 to 000 mg/day of calcium for adults aged 19 to 50 and 1 to 200 mg/day for women over 50 and men over 70. Vitamin D recommendations sit at 600 IU/day for adults up to age 70 and 800 IU/day above that, though many bone specialists target serum 25-hydroxyvitamin D levels of 30 to 50 ng/mL, which often requires 1,500 to 2 to 000 IU/day in deficient patients [10].

A 2022 Cochrane review of 59 trials (N=33,279) found that vitamin D supplementation alone did not reduce fracture incidence in community-dwelling older adults. Calcium plus vitamin D combined, by contrast, reduced hip fracture risk by 16% in institutionalized populations [11]. The take-home is that neither nutrient works in isolation.

Weight-bearing exercise stimulates osteoblast activity through mechanical loading. Resistance training two to three days per week, combined with balance training to reduce fall risk, is endorsed by the American College of Sports Medicine for fracture prevention. Smoking cessation and reducing alcohol to under two standard drinks per day are also evidence-based interventions, as both smoking and heavy alcohol use independently suppress osteoblast function and reduce estrogen levels.

FDA-Approved Pharmacotherapy for Osteoporosis

Bisphosphonates are first-line agents per AACE/ACE 2020 guidelines. Alendronate (70 mg oral weekly), risedronate (35 mg oral weekly or 150 mg monthly), and zoledronic acid (5 mg intravenous once yearly) all reduce vertebral fracture risk by approximately 40% to 70% and hip fracture risk by 40% to 50% in high-risk populations [12]. The Fracture Intervention Trial (FIT, N=6,459) showed that alendronate reduced hip fracture risk by 51% over 3 years in women with prior vertebral fracture (P<0.001) [13].

Denosumab (Prolia, 60 mg subcutaneous every 6 months) is a monoclonal antibody against RANK-L. The FREEDOM trial (N=7,808) demonstrated a 68% reduction in new vertebral fractures and a 40% reduction in hip fractures over 36 months compared to placebo [14]. Denosumab is preferred when renal function is impaired (eGFR <35 mL/min/1.73m²) or when oral bisphosphonate adherence is a barrier.

Teriparatide (Forteo, 20 mcg subcutaneous daily) and abaloparatide (Tymlos, 80 mcg subcutaneous daily) are anabolic agents that stimulate new bone formation. They are reserved for severe osteoporosis or fracture despite antiresorptive therapy. The key teriparatide RCT (N=1,637) showed a 65% reduction in new vertebral fractures over 21 months [15].

Romosozumab (Evenity, 210 mg subcutaneous monthly for 12 months) is a sclerostin inhibitor with both anabolic and antiresorptive properties. The ARCH trial (N=4,093) showed that sequential romosozumab followed by alendronate reduced hip fracture by 38% compared to alendronate alone over 24 months [16]. A cardiovascular safety signal observed in ARCH limits its use in patients with prior myocardial infarction or stroke.

Hormone Therapy and Bone Protection

Menopausal hormone therapy (HRT/MHT) is the most physiologically direct intervention for postmenopausal bone loss. It replaces the estrogen signal that normally keeps osteoclast activity in check.

The Women's Health Initiative (WHI, N=16,608) showed that combined estrogen-progestin therapy reduced hip fracture risk by 33% and vertebral fracture risk by 34% compared to placebo over 5.6 years of follow-up [17]. The estrogen-alone arm (N=10,739 hysterectomized women) produced comparable skeletal benefits. As the 2022 Menopause Society (NAMS) position statement notes: "For women younger than 60 years or within 10 years of menopause onset with no contraindications, the benefit-risk ratio is favorable for treatment of bothersome vasomotor symptoms and for prevention of bone loss." [18]

HRT is not universally recommended solely for fracture prevention, given individualized breast cancer and cardiovascular considerations. For women who have both significant vasomotor symptoms and elevated fracture risk, it may serve both purposes simultaneously. Duration and formulation should be determined by a licensed provider reviewing each patient's complete medical history.

Osteoporosis After Prolonged Glucocorticoid Use

Glucocorticoid-induced osteoporosis (GIOP) is the most common secondary form of the disease. Prednisone at 5 mg/day for more than 3 months causes measurable bone loss; higher doses cause rapid and severe BMD decline within the first 6 to 12 months of exposure [19].

The American College of Rheumatology 2022 GIOP guidelines recommend initiating an oral bisphosphonate in any adult starting glucocorticoids expected to last 3 or more months if they are at moderate or high fracture risk by FRAX criteria. In very high-risk patients, anabolic therapy with teriparatide is preferred over bisphosphonates given evidence of superior BMD response in this subgroup [19]. Calcium 1,000 to 1 to 500 mg/day and vitamin D 600 to 800 IU/day are mandatory co-prescriptions in all patients on chronic glucocorticoids, regardless of baseline BMD.

Monitoring Treatment Response

Repeat DXA is typically performed 1 to 2 years after initiating therapy and every 2 years thereafter if stable. Bone turnover markers, specifically serum C-telopeptide (CTX) for resorption and procollagen type I N-terminal propeptide (P1NP) for formation, can confirm biochemical response within 3 to 6 months, before DXA changes become detectable. A fall in CTX of 50% or more from baseline at 3 months is considered a positive response to antiresorptive therapy.

Patients on bisphosphonates for more than 5 years at moderate risk (or 3 years at high risk) should be evaluated for a drug holiday, given the very small risk of atypical femoral fracture with prolonged use. Denosumab should not be stopped without transitioning to a bisphosphonate, as rebound vertebral fractures have been reported within 12 to 18 months of discontinuation [20].

Special Considerations in Men on TRT

Men starting testosterone replacement therapy who are also at elevated fracture risk represent a distinct clinical group. TRT may both treat hypogonadism and provide skeletal benefit, but it does not replace bisphosphonate therapy when pharmacologic treatment thresholds are met. AACE guidelines recommend baseline DXA in hypogonadal men before starting TRT, with repeat imaging at 1 to 2 years to confirm BMD response [21].

Estradiol levels matter in men on TRT. Men who aromatize testosterone poorly, or who take aromatase inhibitors concurrently, may not receive the full skeletal benefit of TRT because the bone-protective effect depends partly on circulating estradiol, not testosterone alone. A serum estradiol below 20 pg/mL in a man on TRT is associated with accelerated bone loss despite adequate testosterone levels.